Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889718 | 0.86 | KDM4E (0.47) | MEN1KMT2ACHRM3 | |
| SCHEMBL4887400 | 0.77 | KEAP1 (0.47) | SMN1; SMN2CHRM3 | |
| SCHEMBL3042545 | 0.76 | KEAP1 (0.46) | SMN1; SMN2CHRM3 | |
| SCHEMBL3049212 | 0.75 | CHRM2 (0.47) | CHRM3 | |
| SCHEMBL3034639 | 0.75 | ALDH1A1 (0.55) | SMN1; SMN2MEN1KMT2ACHRM3 | |
| SCHEMBL4886443 | 0.74 | CYP11B1 (0.45) | MEN1KMT2A | |
| SCHEMBL3050663 | 0.74 | CHRM2 (0.46) | CHRM3 | |
| SCHEMBL3044573 | 0.74 | POLB (0.55) | SMN1; SMN2MEN1KMT2ACHRM3 | |
| SCHEMBL3044988 | 0.74 | POLB (0.55) | SMN1; SMN2MEN1KMT2ACHRM3 | |
| SCHEMBL4889873 | 0.73 | MEN1 (0.56) | MEN1KMT2ACHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | claimed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | claimed |
| US-20080280883-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-11-13 | — | — | US | disclosed |
| EP-1794161-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032994-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280883-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | SMN1; SMN2 2658/4885MEN1 1629/4885KMT2A 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.